Business Wire

Airship Unveils Airship Journeys, Offering Brands Revolutionary Simplicity to Create, Manage and Optimize Cross-Channel Customer Experiences for the Mobile Era

18.11.2019 17:00:00 EET | Business Wire | Press release

Share

Customer engagement company Airship today introduced Airship Journeys, a new visual interface that makes customer engagement simpler and dramatically more effective for the marketer. Airship Journeys combines the power of visual sequencing and cross-channel branching with glanceable views of goal-based performance to make it easy for marketers to quickly create, manage and adapt customer engagement paths with a few clicks. Now marketers can rapidly leverage their data and models alongside Airship’s real-time mobile data, predictive AI and machine learning to create multichannel sequences that drive improved campaign outcomes and better customer experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005298/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Airship Journeys makes it easy for marketers to rapidly create and optimize multichannel message sequences to reach customers with the right information at the right moment across apps, websites, email, SMS, mobile wallets and more (Graphic: Business Wire)

Airship Journeys addresses frustrations with today’s “drag-and-drop” journey builder tools, which generate convoluted diagrams that are difficult to create and nearly impossible to understand, analyze and modify. A November 2019 Airship survey of marketers found that more than 40% deemed their efforts to manage multichannel digital communications as unsuccessful and more than half said they either have difficulty or can’t identify their best-performing journeys. Over-messaging is a concern to more than 70%, while 55% are also concerned about under-messaging.

“Legacy visual builders were created for an email- and desktop-centric world with far fewer channels and little concern for where a customer was or what they were doing,” said Brett Caine, CEO and president, Airship. “They’ve become complex and bloated in failed attempts to adapt to the new era where the customer experience is all about mobile and in-the-moment responsiveness with many more channels and a much greater expectation that interactions are personalized and contextually relevant. Airship Journeys embeds a decade of mobile expertise and proven AI into a completely new approach to ensure that marketers are successful and their customers have an amazing experience.”

By combining the management of multiple channels into a single console, Airship Journeys makes it easy for marketers to send the right messages to the right customers across apps, websites, email, SMS, mobile wallets and more. Messages can be directed according to priority channel, customer’s preferred channel or fallback channel. Marketer productivity is also enhanced with a unified message composer that allows messages to be composed once and then sent across multiple channels.

“I really like the ease of use, and linking the send time between messages which helped increase productivity for our team. Airship Journeys makes it easy to see what the user experience will look like and share that view internally,” said Conner Fryoux, Digital Product Manager, TGI Fridays. “I'm eager to test out new use cases, and our leadership team is pleased to see more customers come through our doors.”

Airship’s open platform approach also eases the consolidation and application of data and events across channels and existing systems - enabling more precise segmentation and personalized execution. To further enhance contextual responsiveness, Airship Journeys incorporates cross-channel branching that automatically adjusts in real time to respond to a customer’s behavior. Airship Journeys monitors and controls message frequency and uses Predictive AI to segment audiences and automatically re-engage lapsed customers.

“Airship Journeys allows us to make quick decisions and adapt critical journeys on the fly, from driving feature adoption and app store ratings, to increasing transaction frequency at key moments in the lifecycle, all while taking full advantage of our own predictive models and historical data,” said Sam Kirwan, app marketing specialist, Ding.com. “The massive benefit is that Journeys has freed up our time, allowing us to examine cohorts at different life stages and apply more testing as we revamp our lifecycle marketing holistically — no small feat considering our customers span more than 140 countries.”

With early use and guidance by The Allstate Corporation, Ding.com, GameStop, JCPenney, Kohl’s, NBA International and TGI Fridays, Airship Journeys has been designed to meet the complex demands of global brands and is now included in its Customer Engagement Platform.

Recently, among 18 vendors, Airship received the highest Product Scores across all three Use Cases in Gartner’s 2019 Critical Capabilities for Mobile Marketing Platforms,1 including the Acquisition, Engagement and Retention Use Cases. In Gartner’s 2019 Magic Quadrant for Mobile Marketing Platforms 2 Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in the Leaders quadrant overall. Complimentary copies of the reports are available here:

1 Gartner “Critical Capabilities for Mobile Marketing Platforms” by Charles S. Golvin, Mike McGuire, October 21, 2019
2 Gartner “Magic Quadrant for Mobile Marketing Platforms” by Mike McGuire, Charles Golvin, July 15, 2019

Gartner Disclosure

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Airship

Marketing and digital experience teams at thousands of the world’s most admired companies rely on Airship’s Customer Engagement Platform to create deeper connections with customers by delivering incredibly relevant, coordinated messages across channels.

Founded in 2009 as a pioneer in push notifications, Airship now gives brands the user-level data, engagement channels, AI orchestration and services they need to deliver push notifications, emails, SMS, in-app messages, mobile wallet cards and more to exactly the right person in exactly the right moment — building trust, boosting engagement, driving action and growing value.

Learn more about our Customer Engagement Platform, read our blog or follow us on Twitter, LinkedIn, Facebook and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America:
Danielle Stickler
Bateman Group
+1 415-749-9124
airship@bateman-group.com

Corey Gault
Airship
+1 503-206-9164
corey@airship.com

EMEA:
Nina Meyer
Airship
+33 1 44 56 87 10
nina.meyer@airship.com

UK:
Lucinda Layton
Hotwire UK
+44 20 7608 2500
Airship@hotwireglobal.com

France:
Marion Fajgenbaum / Marine Cressot
Hotwire France
+33 14 312 55 68 / 69
AirshipFR@hotwireglobal.com

Germany:
Julia da Silva Bastos
Hotwire Germany
+49 89 2620 81 89
airshipde@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye